BiotechTube

rapcabtagene autoleucel + rituximab

Phase 2Recruiting
0 views this week 0 watching⚡ Active
Interest: 42/100
42
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Scleroderma, Diffuse

Conditions

Scleroderma, Diffuse

Trial Timeline

Oct 29, 2024 → Aug 30, 2032

NCT ID
NCT06655896

About rapcabtagene autoleucel + rituximab

rapcabtagene autoleucel + rituximab is a phase 2 stage product being developed by Novartis for Scleroderma, Diffuse. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06655896. Target conditions include Scleroderma, Diffuse.

Hype Score Breakdown

Clinical
12
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06655896Phase 2Recruiting

Competing Products

15 competing products in Scleroderma, Diffuse

See all competitors
ProductCompanyStageHype Score
IVA337 + PlaceboInventivaPhase 2
29
Cuprimine (penicillamine)MerckPre-clinical
26
STI571NovartisPhase 2
35
Imatinib mesylateNovartisPhase 2
27
imatinib mesylateNovartisPhase 2
35
Mycophenolate mofetilRochePre-clinical
26
Mycophenolate mofetil + Cyclophosphamide + PlaceboRochePhase 2
35
Fludarabine + Cyclophosphamide + ThymoglobulinAmgenPhase 1
21
BMS-986020Bristol Myers SquibbPhase 2
27
dasatinibBristol Myers SquibbPhase 1/2
32
Abatacept + PlaceboBristol Myers SquibbPhase 1/2
32
AVID200Bristol Myers SquibbPhase 1
29
RilonaceptRegeneron PharmaceuticalsPhase 1/2
32
Riociguat + PlaceboBayerPhase 2
32
Riociguat (Adempas, BAY63-2521) + PlaceboBayerPhase 2
32